Form 4: Akero Therapeutics CEO Exercises Stock Options

Akero Therapeutics President and CEO, Andrew Cheng, exercised 52,212 stock options at $0.615 per share, increasing his direct common stock holdings.

Summary

• Andrew Cheng, President and CEO of Akero Therapeutics, Inc. (AKRO), exercised stock options on October 8, 2025.
• He acquired 52,212 shares of common stock at an exercise price of $0.615 per share.
• Following this transaction, Cheng directly owns 526,114 shares of Akero Therapeutics common stock.
• The exercised options were vested and currently exercisable, with an expiration date of September 7, 2028.
• This transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: The filing reports a routine insider transaction (option exercise) which is generally neutral but can be seen as slightly positive due to increased insider ownership, implying confidence. No negative information is present.

Positives

• Increased direct ownership by a key executive, potentially signaling confidence in the company's future prospects.
• The exercise price of $0.615 per share suggests the options were significantly in-the-money, indicating a profitable transaction for the executive.

Risks

• No specific risks are mentioned in this Form 4 filing, which focuses solely on an insider transaction.

Future Outlook

The filing does not provide specific forward-looking statements or guidance, focusing solely on a past insider transaction.

Industry Context

This Form 4 filing details a routine insider transaction (stock option exercise) by a pharmaceutical company executive. Such transactions are common in the biotech and pharmaceutical sectors as part of executive compensation packages, often reflecting the vesting schedule of equity awards. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• This filing reports a standard insider transaction (stock option exercise) which is a common component of executive compensation across all industries, including biotechnology.
• The exercise price of $0.615 per share is specific to the terms of Andrew Cheng's original option grant and cannot be directly compared to specific projects or results of other companies without additional context on Akero Therapeutics' stock performance and compensation structure relative to peers like Madrigal Pharmaceuticals or Viking Therapeutics.

Stakeholder Impact

• Shareholders: Increased direct ownership by the CEO may be viewed positively as a sign of management's confidence in the company's future performance.

Key Dates

Keywords

Akero Therapeutics, AKRO, Andrew Cheng, Stock Option Exercise, Insider Transaction, Form 4, CEO, President, Equity, Beneficial Ownership